The Agency for Medicines and Medical Devices (AMDI) publishes a related report noting the increase in the total value of imported medicines at manufacturers’ prices, indicating the main countries of origin and the dominant therapeutic groups.
Between January and September 2025, the total pharmaceutical market registered a slight increase in value terms, by around 5.5% (from €193.7 million to €204.4 million), while the volume (in packs) increased by 4.6% (from 71.21 million packs to 74.51 million packs).
The annual turnover figures for the pharmaceuticals market over the last five years have tended to increase, but the share of local production in the sales structure is decreasing (8.4% in 2024, 7% in 2025). Substitution is due to the main importing countries; Germany (14%), Romania (10%), Slovenia (8%), Hungary (7%), Turkey (7%). Foreign producers have increased sales on the Moldovan market from 186 million euros in 2021 to 250 million euros in 2024.
According to AMDI, the structure of “the pharmaceutical market correlates with the adjustment of the list of reimbursed medicines by the National Health Insurance Company”. The NHIC determines both the dynamics of imports and local production, directing demand for drugs included in the reimbursed medicines system.
